| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e2a924bc950e7e27df12c024d05e9bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9d6eb5af942986a5a8c1f83e242c035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d678594bd077383f3fc87c8676ab3ae6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-13 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2012-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf2c30cc0db013d026ce7a946fd606f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7be26c36527de41da2f295e722393de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_541391cd1afb8f23265cf7fd45e9ca0c |
| publicationDate |
2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8709812-B2 |
| titleOfInvention |
Drug comprising as the active ingredient proliferative vector containing survivin promoter |
| abstract |
It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of Survivin. The drug may be used in order to treat tumor. In this drug, use may be made of an adenovirus as the vector. In the adenovirus of this drug, an endogenous promoter of an E1A domain may be substituted with a Survivin promoter. |
| priorityDate |
2004-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |